Half-year financial report 2022

This quarter, we took a first step in our strategic transformation by entering the field of oncology with the acquisitions of CellPoint and AboundBio. At the same time, we continue to thoroughly assess and prioritize our current portfolio, while scouting for external innovation. We strongly believe that we are taking the right steps to accelerate value creation, and look forward to presenting an in-depth update later this year.